<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04691245</url>
  </required_header>
  <id_info>
    <org_study_id>3D-US-TAVI</org_study_id>
    <nct_id>NCT04691245</nct_id>
  </id_info>
  <brief_title>3D US Guided Femoral Artery Access for TAVI</brief_title>
  <acronym>3D-US-TAVI</acronym>
  <official_title>Three Dimensional Ultrasound Guided Femoral Access for Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eindhoven University of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Catharina Ziekenhuis Eindhoven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Bleeding and vascular complications of the femoral artery still account for&#xD;
      significant morbidity and mortality in transcatheter aortic valve implantation procedures.&#xD;
      Although steadily declining over the past years through smaller diameter devices and use of&#xD;
      ultrasound, major complications still occur in 3-4 % of patients. Femoral access is often&#xD;
      obtained using 2D US guidance already. New 3D US probes can aid in increasing anatomical&#xD;
      awareness. This can improve first pass success during procedures. Furthermore, for new&#xD;
      closure devices, entering the artery at a straight angle at precisely 12 o'clock probably&#xD;
      reduces complications. Therefore, the investigators hypothesize improved real time needle&#xD;
      guidance using three dimensional ultrasound can decrease procedure related complications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized clinical trial with two arms</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>first pass success</measure>
    <time_frame>during procedure/surgery</time_frame>
    <description>successful entry in femoral artery within one skinbreak and without needle redirections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>imaging time</measure>
    <time_frame>during procedure/surgery</time_frame>
    <description>time from putting probe on skin to start procedure (in seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedure time</measure>
    <time_frame>during procedure/surgery</time_frame>
    <description>time from puncturing skin until entry in femoral artery (in seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total number of punctures</measure>
    <time_frame>during procedure/surgery</time_frame>
    <description>new skin breaks needed for completion of procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of needle redirections</measure>
    <time_frame>during procedure/surgery</time_frame>
    <description>total number of needle withdrawals &gt;5mm but without needing new skin puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 o clock entry</measure>
    <time_frame>during procedure/surgery</time_frame>
    <description>entrance to femoral artery at exactly 12 o clock (antero-medial)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>needle visualization</measure>
    <time_frame>during procedure/surgery</time_frame>
    <description>rated from good-adequate-poor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operator satisfaction</measure>
    <time_frame>during procedure/surgery</time_frame>
    <description>likert scale 1-5 with 1 no satisfaction and 5 completely satisfied</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Ultrasound Therapy; Complications</condition>
  <condition>Femoral Artery Injury</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Femoral access using 3D US</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Femoral access using 2D US</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3D US</intervention_name>
    <description>3D US guided access to femoral artery</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>2D US</intervention_name>
    <description>2D US guided access to femoral artery</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult age (&gt;18 years)&#xD;
&#xD;
          -  Scheduled to undergo elective transcatheter aortic valve implantation with&#xD;
             percutaneous access through the femoral artery&#xD;
&#xD;
          -  Written Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to obtain informed consent&#xD;
&#xD;
          -  Vascular access via alternative approach (radial/subclavian) or surgical cutdown&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Harm Scholten, MD</last_name>
    <phone>0031402398500</phone>
    <phone_ext>2211</phone_ext>
    <email>harm.scholten@cze.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arthur Bouwman, PhD</last_name>
    <phone>0031402398500</phone>
    <phone_ext>2208</phone_ext>
    <email>arthur.bouwman@cze.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Catharina Ziekenhuis Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Harm Scholten, MSc</last_name>
      <phone>+31402398500</phone>
      <email>harm.scholten@catharinaziekenhuis.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 20, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catharina Ziekenhuis Eindhoven</investigator_affiliation>
    <investigator_full_name>Harm Scholten</investigator_full_name>
    <investigator_title>md</investigator_title>
  </responsible_party>
  <keyword>3D Ultrasound</keyword>
  <keyword>vascular access</keyword>
  <keyword>Transcatheter aortic valve implantation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

